Tumor-responsive AAV arms cancer cells to enhance CAR-T cell therapy in solid tumors
Chimeric antigen receptor (CAR)-T-cell therapy remains limited in solid tumors by the scarcity of suitable target antigens and an immunosuppressive tumor microenvironment. Here, we developed a tumor-responsive recombinant adeno-associated virus (rAAV) strategy that harnesses aberrant NF-κB activity to establish a shared synthetic CAR target across tumor types. Using an NF-κB-responsive decoy minimal promoter (DMP), rAAV-SA drove tumor-preferential surface expression of a synthetic antigen (SA), enabling antigen-dependent CAR-T-cell activation, degranulation, and cytotoxicity. Systemic rAAV-SA delivery combined with CAR-T cells produced antitumor activity in triple-negative breast cancer (TNBC) and colorectal cancer xenograft models. We subsequently engineered rAAV-ARMS (antigen redirection and multifunctional secreted effectors), integrating SA expression with tumor-local production of an IL-15/IL-15Rα sushi-domain fusion, CXCL10, and IFN-γ. Compared with antigen redirection alone, rAAV-ARMS enhanced CAR-T-cell-mediated killing in three-dimensional tumor spheroids and, in a TNBC xenograft model, increased intratumoral T-cell accumulation and improved the efficacy of intravenously administered CAR-T cells, without overt systemic toxicity under the conditions examined. These findings establish a tumor-programmed platform for target-redirected universal CAR-T-cell therapy in solid tumors.
Authors
- 谢杏仪
- Yile Wang
- Ziyan Kong
- Yunqi Zhao (ORCID: https://orcid.org/0000-0001-5471-6125)
- Yongqian Shu (ORCID: https://orcid.org/0000-0003-2103-0877)
- Xuhui Wen
- Jinke Wang (ORCID: https://orcid.org/0000-0002-3352-4690)
- Zhimin Fan
- Lu Wang
- Aiwei Yan
Institutions
- Nanjing University of Chinese Medicine (CN)
- Nanjing Traditional Chinese Medicine Hospital (CN)
- Jiangsu Province Hospital (CN)
- Southeast University (CN)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.64898/2026.11.16.766910
- Primary Topic
- CAR-T cell therapy research
- Type
- preprint
Funders
- National Natural Science Foundation of China